@article{78b6d8d2ddba4188995a00b6ddef11b4,
title = "Early diagnosis and management of aggressive posterior vitreoretinopathy presenting in premature neonates",
abstract = "BACKGROUND AND OBJECTIVE: Aggressive posterior vitreoretinopathy (APVR) manifests with a broad area of retinal avascularity, progressive neovascularization, and/or tractional retinal detachment during the neonatal period. PATIENTS AND METHODS: A multicenter, retrospective, observational, consecutive case series study was performed to evaluate the retinal findings and structural retinal outcomes in patients treated for APVR within the first 3 months of life. RESULTS: Three premature neonates with a non-retinopathy of prematurity (ROP) APVR identified during routine ROP screening exams exhibited relatively severe, rapidly progressive retinal vascular abnormalities. Immediate laser photocoagulation of the avascular retina and vitrectomy for traction retinal detachment within several days to weeks improved or stabilized the retinal anatomy in all cases. CONCLUSIONS: This series describes clinical features in APVR in premature infants and suggests that early diagnosis and intervention may mitigate the typical aggressive course and poor prognosis of this condition.",
author = "Gupta, {Mrinali P.} and Yoshihiro Yonekawa and Campbell, {J. Peter} and Irene Rusu and Sarwar Zahid and Patel, {Samir N.} and Felix Chau and Jonas, {Karyn E.} and Erica Oltra and Anton Orlin and Jonathan Chang and Jason Horowitz and Abramson, {David H.} and Brian Marr and Antonio Capone and Chan, {R. V.Paul}",
note = "Funding Information: Originally submitted June 26, 2018. Revision received November 30, 2018. Accepted for publication January 3, 2019. Portions of this study were presented at the Association for Research in Vision and Ophthalmology Annual Meeting, Honolulu, HI, May 2018. Unrestricted departmental funding provided by Research to Prevent Blindness, New York, NY (MPG, RVPC, IR, EO, AO, SNP, KEJ), and National Institute of Health grant P30 EY001792 (RVPC, SZ). Dr. Yonekawa has received personal fees from Allergan, Regeneron, Optos, Alcon, and Alimera outside the submitted work. Dr. Chan has received personal fees from Alcon, Allergan, Visunex, Genentech, and Beyeonics outside the submitted work and is a member of the Scientific Advisory Board for Visunex Medical Systems. The remaining authors report no relevant financial disclosures. Address correspondence to R.V. Paul Chan, MD, FACS, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Department of Ophthalmology & Visual Sciences, 1855 W. Taylor Street, Chicago, IL 60612; email: rvpchan@uic.edu. doi: 10.3928/23258160-20190401-01 Funding Information: Unrestricted departmental funding provided by Research to Prevent Blindness, New York, NY (MPG, RVPC, IR, EO, AO, SNP, KEJ), and National Institute of Health grant P30 EY001792 (RVPC, SZ). Publisher Copyright: {\textcopyright} 2019 Slack Incorporated. All rights reserved.",
year = "2019",
doi = "10.3928/23258160-20190401-01",
language = "English (US)",
volume = "50",
pages = "201--207",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "4",
}